ArticleAntimicrobial agents and chemotherapy2026
Safety evaluation of pretomanid, an anti-tuberculosis drug, for the treatment of pregnant and lactating women.
Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03086486 (A Phase 3 Partially-blinded, Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3 Partially-blinded, Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB), Pre-XDR-TB or Treatment Intolerant or Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Safe and effective treatment options for tuberculosis (TB) are urgently needed for pregnant and lactating women due to the adverse maternal and neonatal outcomes associated with TB disease. Pretomanid is recommended by the World Health Organization for treatment of multidrug-resistant pulmonary TB in combination with bedaquiline and linezolid. However, this regimen is not recommended during pregnancy or breastfeeding due to the absence of clinical safety and efficacy data of pretomanid in these populations. This manuscript presents the nonclinical developmental and reproductive toxicology profile of pretomanid and clinical outcomes of pregnancies in women known to have been exposed to pretomanid. In nonclinical studies, pretomanid did not have a direct effect on fertility and reproductive function in female rats, and no adverse maternal or developmental effects were seen in rats or rabbits up to two times the clinical exposure during organogenesis. Additionally, no adverse developmental effects were observed in pups of pregnant rats orally dosed throughout gestation and lactation at approximately 1.5-fold clinical exposure. In the rat pre- and postnatal development study at 4.4-fold clinical exposure, there was maternal toxicity, lower pup body weights, and a delay in attaining the righting reflex, but no effects on fertility were seen in the male or female rat offspring. Clinically, 11 women became pregnant during pretomanid treatment: 5 had healthy babies, 5 had elective abortions, and 1 had a spontaneous abortion. The weight of evidence from preclinical studies and limited clinical outcomes supports further evaluation of pretomanid use in pregnant or lactating women.CLINICAL TRIALSThis study is registered with ClinicalTrials.gov as NCT03086486.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.